Filing Details

Accession Number:
0001012975-20-000275
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-03 17:52:57
Reporting Period:
2020-02-28
Accepted Time:
2020-03-03 17:52:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1744659 Akero Therapeutics Inc. AKRO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1278411 S Corey Goodman 1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
1329161 J Robert Adelman 1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
1634632 L.p. Ii Fund Strategic Global Venbio 1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
1729408 Venbio Global Strategic Gp Ii, Ltd. 1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
1729409 Venbio Global Strategic Gp Ii, L.p. 1700 Owens Street, Suite 595
San Francisco CA 94158
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-02-28 5,100 $21.30 3,212,667 No 4 S Indirect See footnote
Common Stock Disposition 2020-03-02 10,297 $23.06 3,202,370 No 4 S Indirect See footnote
Common Stock Disposition 2020-03-03 6,401 $23.00 3,195,969 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.08, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $23.49, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
  4. The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020.
  5. These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.